Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model

By afschroeder • July 3, 2026

Lachowiez CA, Zeidner JF, Othman J, Kaempf A, Yun S, Heiblig M, Heuser M, Shahswar R, Madero Marroquin R, Cannova JM, Žučenka A, Marvin-Peek J, Senapati J, Abaza Y, Swaroop A, Zacheo I, Monaco F, Belhabri A, Tauveron-Jalenques U, Tavernier E, Carré M, Aspas Requena G, Cook RJ, Traer E, Saultz JN, O'Nions J, Basheer F, Laurie J, Handa S, Stein EM, Baer MR, Olin R, Blum W, Schiller G, Lin T, Curran E, Yocum A, Madarang E, Daver N, Kadia TM, Marconi G, Madanat Y, Dillon R, DiNardo CD, Swords R, Arango Ossa JE, Watts J, Loghavi S, Pollyea DA, Bernard E; PRISM-AML Investigators. Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model. J Clin Oncol. 2026 Jul 2:JCO2600347. doi: 10.1200/JCO-26-00347. Epub ahead of print. PMID: 42391582.

Tags: Hematology/Oncology, Publications

Related Posts

Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA

Hoff FW, Zeidner JF, Torlapati G, Nicolet D, Mrózek K, Huang Y, Li A, Welkie RL, Swords RT, Traer E, Stein EM, Lin TL, Baer[...]

American Society of Hematology 2026 guidelines for management of relapsed/refractory acute lymphoblastic leukemia in adolescents and young adults

O'Dwyer K, Winestone LE, Cheung MC, Benitez L, Buldini B, Cole PD, Damlaj M, Dholaria B, Dias AL, Dils A, Fritsch M, Greer J, Hayes-Lattin[...]

Identifying the window of aggressive postpartum breast cancer based on the 21-gene Oncotype DX® test in women with HR+, HER2-negative breast cancer

Zhang S, Queen KJ, Duggirala N, Yang E, Lipsyc-Sharf M, Racz J, Bennett J, Hong K, Suresh Y, Hamilton C, Pitta M, Chien N, La[...]